initial public offerings (IPOs) trading on American exchanges

Thursday, July 17, 2014

CareDx (CDNA) began trading on the Nasdaq on 17 July 2014

CareDx Announces Pricing of its IPO and Completion of its First Day of Trading
Brisbane, CA July 17, 2014 CareDx, Inc. (NASDAQ: CDNA) announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $10 per share, before underwriter discounts. In addition, CareDx has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the initial public offering price to cover over -allotments, if any. CareDx completed its first day of trading today on The NASDAQ Global Market under the ticker symbol "CDNA."

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.


3260 Bayshore Blvd
BRISBANE, CA 94005-1021
United States 

No comments:

Post a Comment